Microsatellite Stable Colorectal Cancer Market

DelveInsight's "Microsatellite Stable Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Microsatellite Stable Colorectal Cancer, historical and forecasted epidemiology as well as the Microsatellite Stable Colorectal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Microsatellite Stable Colorectal Cancer market report provides current treatment practices, emerging drugs, Microsatellite Stable Colorectal Cancer market share of the individual therapies, current and forecasted Microsatellite Stable Colorectal Cancer market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Microsatellite Stable Colorectal Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Microsatellite Stable Colorectal Cancer market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2019-2032

Microsatellite Stable Colorectal Cancer Disease Understanding and Treatment Algorithm

The most prominent kind of cancer affecting the colon and rectum is colorectal cancer (CRC). Colorectal cancer with microsatellite stability (MSS), which has chromosomal instability, accounts for 85 percent of tumors. They are caused by mutations in genes needed for chromosomal stability, resulting in the accumulation of chromosomal gains and losses (aneuploidy), as well as structural chromosomal rearrangements. They are one of the most mutated tumor kinds in terms of the number of tumor genetic mutations.

 

Symptoms of Colorectal cancer might include: Change in bowel habits, Discomfort in abdomen, Rectal Bleeding, Changes in stool consistency, Constipation and diarrhea.

 

Because microsatellite stable colorectal cancer shows less signals that warn the immune system of the presence of cancer, checkpoint inhibitors such as nivolumab have been ineffective in treating microsatellite stable colorectal cancer. Clinical studies for developing a potential drug for MSS colorectal cancer have been ongoing

 

Microsatellite Stable Colorectal Cancer Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Microsatellite Stable Colorectal Cancer.

 

Microsatellite Stable Colorectal Cancer Treatment

It covers the details of conventional and current medical therapies available in the Microsatellite Stable Colorectal Cancer market for the treatment of the condition. It also provides Microsatellite Stable Colorectal Cancer treatment algorithms and guidelines in the United States, Europe, and Japan.

Microsatellite Stable Colorectal Cancer Epidemiology 

The Microsatellite Stable Colorectal Cancer epidemiology section provides insights about the historical and current Microsatellite Stable Colorectal Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Microsatellite Stable Colorectal Cancer market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Microsatellite Stable Colorectal Cancer Key Findings

  • Approximately 85 percent of instances of non-metastatic colorectal cancer (CRC) are associated with chromosomal instability and a proficient DNA Mismatch-Repair mechanism (pMMR); these cases are also known as CRC with microsatellite stability (MSS). 
  • In the United States, an estimated 104,610 new cases of colon cancer and 43,340 cases of rectal cancer will be diagnosed in 2020
  • Men have a 30% greater CRC incidence rate than women. 
  • In their lifetime, around 4.4 percent of males (1 in 23) and 4.1 percent of women (1 in 25) will be diagnosed with CRC. Lifetime risk is equivalent in men and women, despite greater incidence rates in males because of women's longer life expectancy.
  • The relative survival rate for Colorectal cancer is 64 percent after 5 years of diagnosis and 58 percent after 10 years of diagnosis.

 

Country Wise- Microsatellite Stable Colorectal Cancer Epidemiology

The epidemiology segment also provides the Microsatellite Stable Colorectal Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Microsatellite Stable Colorectal Cancer Drug Chapters

The drug chapter segment of the Microsatellite Stable Colorectal Cancer report encloses the detailed analysis of Microsatellite Stable Colorectal Cancer marketed drugs and late-stage (Phase-III and Phase-II) Microsatellite Stable Colorectal Cancer pipeline drugs. It also helps to understand the Microsatellite Stable Colorectal Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Microsatellite Stable Colorectal Cancer Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Microsatellite Stable Colorectal Cancer treatment.

 

Key Microsatellite Stable Colorectal Cancer Companies

  • Gritstone Oncology
  • Merck Sharp & Dohme Corp.
  • Arrys Therapeutics
  • NeoImmuneTec

 

Microsatellite Stable Colorectal Cancer Pipeline Drugs

  • GRANITE
  • MK7123-034
  • and Many more

Microsatellite Stable Colorectal Cancer Market Outlook

The Microsatellite Stable Colorectal Cancer market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Microsatellite Stable Colorectal Cancer market trends by analyzing the impact of current Microsatellite Stable Colorectal Cancer therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Microsatellite Stable Colorectal Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Microsatellite Stable Colorectal Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Microsatellite Stable Colorectal Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Microsatellite Stable Colorectal Cancer Key Findings

This section includes a glimpse of the Microsatellite Stable Colorectal Cancer market in 7MM.

 

The United States Microsatellite Stable Colorectal Cancer Market Outlook

This section provides the total Microsatellite Stable Colorectal Cancer market size and market size by therapies in the United States.

 

EU-5 Countries: Microsatellite Stable Colorectal Cancer Market Outlook

The total Microsatellite Stable Colorectal Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

 

Japan Microsatellite Stable Colorectal Cancer Market Outlook

The total Microsatellite Stable Colorectal Cancer market size and market size by therapies in Japan is also mentioned.

Microsatellite Stable Colorectal Cancer Drugs Uptake

This section focuses on the rate of uptake of the potential Microsatellite Stable Colorectal Cancer drugs recently launched in the Microsatellite Stable Colorectal Cancer market or expected to get launched in the market during the study period 2019-2032. The analysis covers Microsatellite Stable Colorectal Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Microsatellite Stable Colorectal Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Microsatellite Stable Colorectal Cancer market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Microsatellite Stable Colorectal Cancer Pipeline Development Activities

The Microsatellite Stable Colorectal Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Microsatellite Stable Colorectal Cancer key players involved in developing targeted therapeutics.

 

Reimbursement Scenario in Microsatellite Stable Colorectal Cancer

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Microsatellite Stable Colorectal Cancer market trends, we take KOLs and SMEs ' opinion working in the Microsatellite Stable Colorectal Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Microsatellite Stable Colorectal Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Microsatellite Stable Colorectal Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Microsatellite Stable Colorectal Cancer Market Report

  • The report covers the descriptive overview of Microsatellite Stable Colorectal Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Microsatellite Stable Colorectal Cancer epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Microsatellite Stable Colorectal Cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Microsatellite Stable Colorectal Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Microsatellite Stable Colorectal Cancer market

 

Report Attribute/Metric Details
Study Period 2019- 2032
Geographies Covered 7MM
Market Size USD XX Million
CAGR XX%
Key Companies
  • Gritstone Oncology
  • Merck Sharp & Dohme Corp.
  • Arrys Therapeutics
  • NeoImmuneTec

Microsatellite Stable Colorectal Cancer Market Report Highlights

  • In the coming years, the Microsatellite Stable Colorectal Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Microsatellite Stable Colorectal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Microsatellite Stable Colorectal Cancer. The launch of emerging therapies will significantly impact the Microsatellite Stable Colorectal Cancer market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Microsatellite Stable Colorectal Cancer
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Microsatellite Stable Colorectal Cancer Report Insights

  • Microsatellite Stable Colorectal Cancer Patient Population
  • Therapeutic Approaches
  • Microsatellite Stable Colorectal Cancer Pipeline Analysis
  • Microsatellite Stable Colorectal Cancer Market Size
  • Microsatellite Stable Colorectal Cancer Market Trends
  • Microsatellite Stable Colorectal Cancer Market Opportunities
  • Impact of upcoming Microsatellite Stable Colorectal Cancer Therapies

Microsatellite Stable Colorectal Cancer Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Microsatellite Stable Colorectal Cancer Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Microsatellite Stable Colorectal Cancer Market
  • Microsatellite Stable Colorectal Cancer Drugs Uptake

Microsatellite Stable Colorectal Cancer Report Assessment

  • Current Treatment Practices
  • Microsatellite Stable Colorectal Cancer Unmet Needs
  • Microsatellite Stable Colorectal Cancer Pipeline Product Profiles
  • Microsatellite Stable Colorectal Cancer Market Attractiveness
  • Microsatellite Stable Colorectal Cancer Market Drivers
  • Microsatellite Stable Colorectal Cancer Market Barriers

Key Questions

Microsatellite Stable Colorectal Cancer Market Insights:

  • What was the Microsatellite Stable Colorectal Cancer drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Microsatellite Stable Colorectal Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Microsatellite Stable Colorectal Cancer market size during the forecast period (2019-2032)?
  • At what CAGR, the Microsatellite Stable Colorectal Cancer market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the Microsatellite Stable Colorectal Cancer market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Microsatellite Stable Colorectal Cancer market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Microsatellite Stable Colorectal Cancer Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of the Microsatellite Stable Colorectal Cancer?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Microsatellite Stable Colorectal Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Microsatellite Stable Colorectal Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Microsatellite Stable Colorectal Cancer?
  • Out of all 7MM countries, which country would have the highest prevalent population of Microsatellite Stable Colorectal Cancer during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Microsatellite Stable Colorectal Cancer treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of Microsatellite Stable Colorectal Cancer in the USA, Europe, and Japan?
  • What are the Microsatellite Stable Colorectal Cancer marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Microsatellite Stable Colorectal Cancer?
  • How many therapies are in-development by each company for Microsatellite Stable Colorectal Cancer treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Microsatellite Stable Colorectal Cancer treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Microsatellite Stable Colorectal Cancer therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Microsatellite Stable Colorectal Cancer and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Microsatellite Stable Colorectal Cancer?
  • What are the global historical and forecasted market of Microsatellite Stable Colorectal Cancer?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Microsatellite Stable Colorectal Cancer market
  • To understand the future market competition in the Microsatellite Stable Colorectal Cancer market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Microsatellite Stable Colorectal Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Microsatellite Stable Colorectal Cancer market
  • To understand the future market competition in the Microsatellite Stable Colorectal Cancer market

1. Key Insights

2. Executive Summary of Microsatellite Stable Colorectal Cancer

3. Competitive Intelligence Analysis for Microsatellite Stable Colorectal Cancer

4. Microsatellite Stable Colorectal Cancer: Market Overview at a Glance

4.1. Microsatellite Stable Colorectal Cancer Total Market Share (%) Distribution in 2019

4.2. Microsatellite Stable Colorectal Cancer Total Market Share (%) Distribution in 2032

5. Microsatellite Stable Colorectal Cancer: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Microsatellite Stable Colorectal Cancer Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Microsatellite Stable Colorectal Cancer Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Microsatellite Stable Colorectal Cancer Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Microsatellite Stable Colorectal Cancer Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Microsatellite Stable Colorectal Cancer Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Microsatellite Stable Colorectal Cancer Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Microsatellite Stable Colorectal Cancer Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Microsatellite Stable Colorectal Cancer Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Microsatellite Stable Colorectal Cancer Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Microsatellite Stable Colorectal Cancer Treatment and Management

8.2. Microsatellite Stable Colorectal Cancer Treatment Algorithm

9. Microsatellite Stable Colorectal Cancer Unmet Needs

10. Key Endpoints of Microsatellite Stable Colorectal Cancer Treatment

11. Microsatellite Stable Colorectal Cancer Marketed Products

11.1. List of Microsatellite Stable Colorectal Cancer Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Microsatellite Stable Colorectal Cancer Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Microsatellite Stable Colorectal Cancer: Seven Major Market Analysis

13.1. Key Findings

13.2. Microsatellite Stable Colorectal Cancer Market Size in 7MM

13.3. Microsatellite Stable Colorectal Cancer Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Microsatellite Stable Colorectal Cancer Total Market Size in the United States

15.1.2. Microsatellite Stable Colorectal Cancer Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Microsatellite Stable Colorectal Cancer Total Market Size in Germany

15.3.2. Microsatellite Stable Colorectal Cancer Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Microsatellite Stable Colorectal Cancer Total Market Size in France

15.4.2. Microsatellite Stable Colorectal Cancer Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Microsatellite Stable Colorectal Cancer Total Market Size in Italy

15.5.2. Microsatellite Stable Colorectal Cancer Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Microsatellite Stable Colorectal Cancer Total Market Size in Spain

15.6.2. Microsatellite Stable Colorectal Cancer Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Microsatellite Stable Colorectal Cancer Total Market Size in the United Kingdom

15.7.2. Microsatellite Stable Colorectal Cancer Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Microsatellite Stable Colorectal Cancer Total Market Size in Japan

15.8.3. Microsatellite Stable Colorectal Cancer Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Microsatellite Stable Colorectal Cancer

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

List of Table

Table 1: 7MM Microsatellite Stable Colorectal Cancer Epidemiology (2019-2032)

Table 2: 7MM Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases (2019-2032)

Table 3: Microsatellite Stable Colorectal Cancer Epidemiology in the United States (2019-2032)

Table 4: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Microsatellite Stable Colorectal Cancer Epidemiology in Germany (2019-2032)

Table 6: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Microsatellite Stable Colorectal Cancer Epidemiology in France (2019-2032)

Table 8: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Microsatellite Stable Colorectal Cancer Epidemiology in Italy (2019-2032)

Table 10: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Microsatellite Stable Colorectal Cancer Epidemiology in Spain (2019-2032)

Table 12: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Microsatellite Stable Colorectal Cancer Epidemiology in the UK (2019-2032)

Table 14: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in the UK (2019-2032)

Table 15: Microsatellite Stable Colorectal Cancer Epidemiology in Japan (2019-2032)

Table 16: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in Japan (2019-2032)

Table 17: Drug Name, Clinical Trials by Recruitment status

Table 18: Drug Name, Clinical Trials by Zone

Table 19: Total Seven Major Market Size in USD, Million (2019-2032)

Table 20: Region-wise Market Size in USD, Million (2019-2032)

Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Table 22: United States Market Size in USD, Million (2019-2032)

Table 23: United States Market Size by Therapy in USD, Million (2019-2032)

Table 24: Germany Market Size in USD, Million (2019-2032)

Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Table 26: France Market Size in USD, Million (2019-2032)

Table 27: France Market Size by Therapy in USD, Million (2019-2032)

Table 28: Italy Market Size in USD, Million (2019-2032)

Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Table 30: Spain Market Size in USD, Million (2019-2032)

Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Table 32: United Kingdom Market Size in USD, Million (2019-2032)

Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Table 34: Japan Market Size in USD, Million (2019-2032)

Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM Microsatellite Stable Colorectal Cancer Epidemiology (2019-2032)

Figure 2: 7MM Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases (2019-2032)

Figure 3: Microsatellite Stable Colorectal Cancer Epidemiology in the United States (2019-2032)

Figure 4: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5: Microsatellite Stable Colorectal Cancer Epidemiology in Germany (2019-2032)

Figure 6: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7: Microsatellite Stable Colorectal Cancer Epidemiology in France (2019-2032)

Figure 8: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in France (2019-2032)

Figure 9: Microsatellite Stable Colorectal Cancer Epidemiology in Italy (2019-2032)

Figure 10: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11: Microsatellite Stable Colorectal Cancer Epidemiology in Spain (2019-2032)

Figure 12: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13: Microsatellite Stable Colorectal Cancer Epidemiology in the UK (2019-2032)

Figure 14: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in the UK (2019-2032)

Figure 15: Microsatellite Stable Colorectal Cancer Epidemiology in Japan (2019-2032)

Figure 16: Microsatellite Stable Colorectal Cancer Diagnosed and Treatable Cases in Japan (2019-2032)

Figure 17: Drug Name, Clinical Trials by Recruitment status

Figure 18: Drug Name, Clinical Trials by Zone

Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)

Figure 20: Region-wise Market Size in USD, Million (2019-2032)

Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Figure 22: United States Market Size in USD, Million (2019-2032)

Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)

Figure 24: Germany Market Size in USD, Million (2019-2032)

Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Figure 26: France Market Size in USD, Million (2019-2032)

Figure 27: France Market Size by Therapy in USD, Million (2019-2032)

Figure 28: Italy Market Size in USD, Million (2019-2032)

Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Figure 30: Spain Market Size in USD, Million (2019-2032)

Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Figure 32: United Kingdom Market Size in USD, Million (2019-2032)

Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Figure 34: Japan Market Size in USD, Million (2019-2032)

Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of figures is not exhaustive; the final content may vary

  • Gritstone Oncology
  • Merck Sharp & Dohme Corp.
  • Arrys Therapeutics
  • NeoImmuneTec

Forward to Friend

Need A Quote